NOL

Fossil Group, Inc. Reports First Quarter 2024 Financial Results

Retrieved on: 
Mittwoch, Mai 8, 2024
TAG, Information, Rationalization, Annual report, Security (finance), Inventory, Regulation, CARES Act, Privacy, Operating cost, Terrorism, Failure, FOSL, Intellectual property, Fossil Group, Interim, NOL, GAAP, Growth, Bank

RICHARDSON, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the first quarter ended March 30, 2024.

Key Points: 
  • RICHARDSON, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the first quarter ended March 30, 2024.
  • As a percentage of net sales, operating expenses were 63.8% in the first quarter of 2024 compared to 60.9% in the prior year first quarter.
  • Operating margin of (11.5)% in the first quarter of 2024 was flat with the prior year first quarter.
  • Adjusted operating margin was (7.5)% in the first quarter of 2024 compared to (7.7)% in the prior year first quarter.

Virco Reports Full Year Revenue Increased 16.5% to $269.1 million, delivering 32.4% growth in Net Income

Retrieved on: 
Freitag, April 12, 2024
VIRC, School, Management, Forward, Growth, History, Administration, Tax, Optimism, NOL

Net revenue for the full year ended January 31, 2024 increased 16.5% to $269.1 million from $231.1 million in the prior year.

Key Points: 
  • Net revenue for the full year ended January 31, 2024 increased 16.5% to $269.1 million from $231.1 million in the prior year.
  • For the seasonally light fourth quarter, revenue increased 9.8% to $42.6 million from $38.8 million.
  • Operating Income for the full year ended January 31, 2024 was $31.9 million compared to $10.6 million the prior year.
  • Total Net Income after taxes for the full year was $21.9 million compared to $16.5 million the prior year.

Ellington Credit Adopts Tax Asset Preservation Plan Designed to Protect Shareholder Value by Preserving the Availability of Its Net Operating Losses While Operating as a C-Corp

Retrieved on: 
Dienstag, April 23, 2024
Professional Services, Residential Building & Real Estate, Finance, Construction & Property, REIT, Accounting, Investment, Nature, RIC, Annual report, Trustee, Consumption tax, Internal Revenue Code, IRC, NOL, Person, Security (finance)

Ellington Credit Company (“Ellington Credit” or the “Company”) (NYSE: EARN) announced today that it has adopted a shareholder rights plan designed to protect shareholder value by preserving the availability of the Company’s net operating loss carryforwards (“NOLs”) and other tax attributes under the Internal Revenue Code of 1986, as amended (the “IRC”) (such plan, the “Tax Asset Preservation Plan”).

Key Points: 
  • Ellington Credit Company (“Ellington Credit” or the “Company”) (NYSE: EARN) announced today that it has adopted a shareholder rights plan designed to protect shareholder value by preserving the availability of the Company’s net operating loss carryforwards (“NOLs”) and other tax attributes under the Internal Revenue Code of 1986, as amended (the “IRC”) (such plan, the “Tax Asset Preservation Plan”).
  • The Tax Asset Preservation Plan is substantially similar to those adopted by numerous other public companies with significant NOLs.
  • The Company’s Board of Directors has the discretion to exempt any person or group from the provisions of the Tax Asset Preservation Plan.
  • Additional information about the Tax Asset Preservation Plan will be available on a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

IMUNON Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, März 28, 2024
Transfer, Ovarian cancer, Immunotherapy, Patient, Lung, Vaccine, Good manufacturing practice, Sale, CMC, IND, Bangladesh Technical Education Board, IPR, Investment, Clinical trial, Neoplasm, Research, Primate, DNA, NOL, MD Anderson Cancer Center, Trial of the century, ITT, Safety, MRD, Interim, Silicon Valley Bank, Vaccination, Food, CMOS, Elsevier, CD8, Drug discovery, SVB, CRS, University, Death, SARS-CoV-2, Earnings call, Lassa mammarenavirus, PFS, Immunoglobulin G, FDA, OS, CD4, Temperature, Progression-free survival, COVID-19, Mouse, Messenger, Human, Wistar Institute, Hospital

LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

Key Points: 
  • “We remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.
  • In September 2023, the Company announced interim PFS and OS data with IMNN-001 in its OVATION 2 Study.
  • The Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m. Eastern time today.
  • To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

Retrieved on: 
Montag, März 25, 2024
Transfer, Growth, Biotechnology, CFO, Research, NOL, Sale, Drug development, Workforce

LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses (NOLs). The NOL sales are administered through the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program. This non-dilutive funding further strengthens the Company’s balance sheet.

Key Points: 
  • LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses (NOLs).
  • The NOL sales are administered through the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program.
  • “This program offered by the NJEDA provides IMUNON with investor-friendly ways to finance its clinical development programs,” said Jeffrey W. Church, IMUNON’s executive vice president and CFO.
  • IMUNON is one of several biotechnology/technology companies to qualify in this competitive process to share in the funding this year.

Destination XL Group, Inc. Reports Fiscal 2023 Fourth Quarter and  Full-Year Financial Results

Retrieved on: 
Donnerstag, März 21, 2024
E-commerce, Untuckit, Destination XL Group, Comparable, Tax, Growth, Male, Capital expenditure, History, NOL, Shoe, Investment, Interest, Depreciation, Income tax, DXL, Marketing, Corporation, Security (finance)

Comparable sales for the fourth quarter decreased 10.1% as compared to the fourth quarter of fiscal 2022.

Key Points: 
  • Comparable sales for the fourth quarter decreased 10.1% as compared to the fourth quarter of fiscal 2022.
  • For the 14-week fourth quarter of fiscal 2023, total sales were $137.1 million as compared to $143.9 million for the 13-week fourth quarter of fiscal 2022.
  • SG&A expenses for the fourth quarter of fiscal 2023 were 38.5% of sales, compared with 37.8% in the fourth quarter of fiscal 2022.
  • Interest income for the fourth quarter of fiscal 2023 was $0.7 million, as compared to interest income of $0.1 million for the fourth quarter of fiscal 2022.

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, März 21, 2024
Research, MPV, IIM, MuSK protein, Toxicity, Conference, Disease, Dermatomyositis, Juvenile dermatomyositis, Federation, Patient, NOL, Observation, CRS, SLE, Health Canada, IND, Immunoglobulin therapy, Pemphigus, Investment, Investigational New Drug, Myopathy, Systemic scleroderma, Marketing, FDA, Clinical trial, Cytokine release syndrome, Cyclophosphamide, CD19, Food, Autoimmune disease, Pharmaceutical industry

In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.

Key Points: 
  • In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.
  • In November 2023, Cabaletta announced that its IND application for CABA-201 was allowed to proceed by the FDA for the Phase 1/2 RESET-MG trial.
  • Cabaletta anticipates reporting initial clinical data from the Phase 1/2 RESET-MG trial in the second half of 2024.
  • As of December 31, 2023, Cabaletta had cash, cash equivalents and short-term investments of $241.2 million, compared to $106.5 million as of December 31, 2022.

Hudson Global Reports 2023 Fourth Quarter and Full-Year Results

Retrieved on: 
Donnerstag, März 14, 2024
RPO, Environment, Webcast, COVID-19, History, NOL, Table, OLD, GAAP, Workforce, Share repurchase, Video game

OLD GREENWICH, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (Nasdaq: HSON), a leading global talent solutions company, announced today financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • OLD GREENWICH, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (Nasdaq: HSON), a leading global talent solutions company, announced today financial results for the fourth quarter and full year ended December 31, 2023.
  • Jeff Eberwein, Chief Executive Officer at Hudson Global, said, "Our fourth quarter financial results continued to reflect the year-over-year impact of the slowdown in the US technology sector and as well as fourth quarter hiring delays at certain clients, which we expect to recover beginning in the second quarter of 2024.
  • Asia Pacific delivered adjusted EBITDA of $0.9 million in the fourth quarter of 2023 versus adjusted EBITDA of $2.1 million in the fourth quarter of 2022.
  • The Company generated $3.3 million in cash flow from operations in the fourth quarter of 2023 compared to $4.4 million in the fourth quarter of 2022.

Ocean Power Technologies, Inc. Announces Third Quarter Fiscal 2024 Results

Retrieved on: 
Mittwoch, März 13, 2024
Transfer, Government, Conference, Letter, Net, Growth, OPT, CFO, Intelligence, Shareholder, Telephone, MDAS, Research, NOL, Controller, Carbon, Build automation, Ocean Power Technologies, Investment, AT&T, Primary energy, Court, Engineering

MONROE TOWNSHIP, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), today announced financial results for its fiscal third quarter ended January 31, 2024 (“Q324”), including year over year revenue, gross profit, and pipeline growth.

Key Points: 
  • MONROE TOWNSHIP, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), today announced financial results for its fiscal third quarter ended January 31, 2024 (“Q324”), including year over year revenue, gross profit, and pipeline growth.
  • The gross margin rate was 49.7% and 21.1%, for the nine months ended January 31, 2024, and 2023, respectively.
  • In February 2024, the Company received multiple orders for fully integrated WAM-V Unmanned Surface Vehicles (USVs) totaling over $1.25 million.
  • Operating expenses were $8.6 million in Q324, materially in-line with the second quarter of fiscal 2024 from and up from $6.8 million in Q323.

Kidpik and Nina Footwear Announce Entry Into Definitive Merger Agreement

Retrieved on: 
Montag, April 1, 2024
Retail, Footwear, Online Retail, Fashion, Growth, NOL, Shoe, PIK, Dogcart, Mining

Kidpik Corp. (NASDAQ: PIK) (“Kidpik”), a kids’ online clothing subscription-based e-commerce company, and Nina Footwear Corp., a private company operating a brand specializing in women’s and kids’ dress shoes and accessories for special occasions (“Nina Footwear”), today announced that they have entered into a definitive merger agreement.

Key Points: 
  • Kidpik Corp. (NASDAQ: PIK) (“Kidpik”), a kids’ online clothing subscription-based e-commerce company, and Nina Footwear Corp., a private company operating a brand specializing in women’s and kids’ dress shoes and accessories for special occasions (“Nina Footwear”), today announced that they have entered into a definitive merger agreement.
  • In connection with the merger, Nina Footwear stockholders will be issued shares of common stock of Kidpik such that upon closing thereof, Nina Footwear’s stockholders will own 80% of Kidpik’s outstanding common stock.
  • Kidpik is controlled by Mr. Ezra Dabah, the Chief Executive Officer, Chairman, and majority stockholder (67% beneficial owner) of Kidpik, who is also the Chief Executive Officer of Nina Footwear.
  • Mr. Dabah and his children own approximately 79.3% of Nina Footwear, and Mr. Dabah and his extended family own 100% of Nina Footwear.